NanoString Technologies Inc. Receives Canadian Market Approval For Its Prosigna Breast Cancer Prognostic Gene Signature Assay

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received a Class III Medical Device License from Health Canada, clearing the company to market its Prosigna® Breast Cancer Prognostic Gene Signature Assay for assessing a woman’s 10-year risk of distant recurrence and accurately identifying the intrinsic biologic subtype of the tumor.

Help employers find you! Check out all the jobs and post your resume.